Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine
2000
Chemotherapy for Advanced Medullary Thyroid Cancer
Sample size: 20
publication
Evidence: moderate
Author Information
Author(s): Nocera M, Baudin E, Pellegriti G, Cailleux A F, Mechelany-Corone C, Schlumberger M
Primary Institution: Institute Gustave-Roussy
Hypothesis
Can an alternating combination of doxorubicin-streptozocin and 5-FU-dacarbazine effectively treat advanced medullary thyroid cancer?
Conclusion
The study found that the alternating chemotherapy regimen led to three partial responses and ten long-term stabilizations without unexpected toxicity.
Supporting Evidence
- Three partial responses were observed in the study.
- Ten long-term stabilizations were achieved.
- No unexpected toxicity occurred during treatment.
Takeaway
Doctors tried a new mix of medicines to help people with a type of thyroid cancer, and it worked for some of them without causing bad side effects.
Methodology
Patients received alternating combinations of doxorubicin-streptozocin and 5-FU-dacarbazine.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website